Watson buys Andrx for $1.9 billion
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Watson Pharmaceuticals |
Andrx |
$1.9B buyout |
The deal makes Watson the third largest generic drug maker in the country. |
|
Pharmos |
Vela Pharmaceuticals |
$29.7M buyout |
Vela specializes in medicines related to diseases of the nervous system. |
|
Serologicals |
Cytomix |
Buyout |
Serologicals is buying Cytomix for an undisclosed sum. |
|
Alchemia |
Meditech Research |
$16.9M merger |
The companies will merge by way of an off-market takeover bid. |
|
BioScrip |
Intravenous Therapy Services |
$13M acquisition |
Bioscripts has acquired ITS for $13 million plus earn-out payments. |
|
PharmAthene |
Siga Technologies |
Merger |
The merger will create a company focused on biodefense. |
|
Novartis |
Infinity |
$400M deal |
The alliance will concentrate on developing new treatments involving Bcl-2 protein family members. |
|
FEI Company |
Sidec Technologies |
Collaboration |
The companies will collaborate on the commercialization of Protein Tomography solutions and services. |
|
GlaxoSmithKline |
Myogen |
$100M licensing deal |
Myogen has licensed its therapy for pulmonary arterial hypertension to for $20 million up front and $80 million in potential milestones. |
|
Cook Group |
AVI BioPharma |
$100 licensing deal |
Cook Group is licensing AVI's Neugene antisense technology for developing new therapies for vascular diseases. |
|
Novartis |
Emisphere Technologies |
$30M licensing deal |
Novartis has executed its license option to develop oral parathyroid hormone using Emisphere's technology. |
|
Medicis |
Inamed |
Licensing deal |
Medicis licensed the experimental anti-wrinkle drug Reloxin from French drug manufacturer Ipsen. |
|
Takeda Pharmaceutical |
Lexicon Genetics |
Licensing deal |
In 2004, the companies entered into a partnership under which Takeda can purchase promising targets that were discovered in Lexicon's Genome5000 program. |